Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provide

Additional data presented from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors. Cytokine data reveal extended PK profile for SON-1010:Induces prolonged

Related Keywords

United States , Singapore , Australia , India , American , Michaelv Morabito , Jay Cross , Pankaj Mohan , Richard Kenney , American Association For Cancer Research Annual Meeting , Life Therapeutics Pte Ltd , Solebury Strategic Communications , Securities Exchange , Sonnet Biotherapeutics Holdings Inc , Exchange Commission , American Association For Cancer Research , Nasdaq , Sonnet Biotherapeutics Inc View , Sonnet Founder , Chief Executive , Cancer Research Annual Meeting , Recent Corporate , Master Clinical Trial , Supply Agreement , Safety Agreements , Cancer Research , Fully Human Albumin Binding , New Life Therapeutics Pte , New Life , Sonnet Chief Medical , Quarter Ended March , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Months Ended March , Inc View , Gefallene Big Techs , Jsonnet , Iotherapeutics , Rovides , Iscal , Ear , 023 , Second , Quarter , Gate , Business , Earnings , Update ,